Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Melody A. Cobleigh"'
Autor:
Vincent Antao, Mohammad Jahanzeb, Denise A. Yardley, Joyce O'Shaughnessy, Peter A. Kaufman, Ginny Mason, Adam Brufsky, Sara A. Hurvitz, Laura Chu, Melody A. Cobleigh, Hope S. Rugo, Sandra M. Swain, Debu Tripathy, Haocheng Li
Publikováno v:
Clinical Cancer Research. 26:1105-1113
Purpose: We report treatments and outcomes in a contemporary patient population with HER2-positive metastatic breast cancer (MBC) by hormone receptor (HR) status from the Systemic Therapies for HER2-positive Metastatic Breast Cancer Study (SystHERs).
Autor:
Sandra M. Swain, Vincent Antao, Haocheng Li, Debu Tripathy, Joyce O'Shaughnessy, Laura Chu, Ginny Mason, Peter A. Kaufman, Denise A. Yardley, Sara A. Hurvitz, Mohammad Jahanzeb, Adam Brufsky, Hope S. Rugo, Melody A. Cobleigh
Publikováno v:
The oncologist, vol 25, iss 2
The Oncologist
The Oncologist
Background Limited data exist describing real‐world treatment of de novo and recurrent HER2‐positive metastatic breast cancer (MBC). Materials and Methods The Systemic Therapies for HER2‐Positive Metastatic Breast Cancer Study (SystHERs) was a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f85b6f5b4b0427599690acf0ecde9c9
https://escholarship.org/uc/item/3141135z
https://escholarship.org/uc/item/3141135z
Autor:
Timothy Yung, Melody A. Cobleigh, Abde M. Abukhdeir, Deri Morgan, Molly DiScala, Matthew S. Najor
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 6, p e0234146 (2020)
PLoS ONE, Vol 15, Iss 6, p e0234146 (2020)
Approximately 20% of breast cancers are HER2-positive. Trastuzumab has improved patient outcomes significantly for these cancers. However, acquired resistance remains a major hurdle in the clinical management of these patients. Therefore, identifying
Autor:
Haocheng Li, Ginny Mason, Denise A. Yardley, Sara A. Hurvitz, Melody A. Cobleigh, Sandra M. Swain, Adam Brufsky, Hope S. Rugo, Mohammad Jahanzeb, Peter A. Kaufman, Debu Tripathy, Vincent Antao, Laura Chu, Joyce O'Shaughnessy
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(8)
Purpose:Patients with HER2-positive metastatic breast cancer (MBC) with central nervous system (CNS) metastasis have a poor prognosis. We report treatments and outcomes in patients with HER2-positive MBC and CNS metastasis from the Systemic Therapies